|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2002, Vol. 99, No. 6, pp. 1909-1912
PERSPECTIVE
Genetic pathways in therapy-related myelodysplasia and acute
myeloid leukemia
Jens Pedersen-Bjergaard,
Mette K. Andersen,
Debes H. Christiansen, and
Claus Nerlov
From the Cytogenetic Laboratory, Section of
Hematology/Oncology, Department of Clinical Genetics, the Juliane Marie
Center and the Laboratory of Gene Therapy Research, the Laboratory
Center, Rigshospitalet, University Hospital of Copenhagen, Denmark.
Therapy-related acute myeloid leukemia (t-AML) in most cases
develops after chemotherapy of other malignancies and shows
characteristic chromosome aberrations. Two general types of t-AML have
previously been identified. One type is observed after therapy with
alkylating agents and characteristically presents as therapy-related
myelodysplasia with deletions or loss of the long arms of chromosomes 5 and 7 or loss of the whole chromosomes. The other type is observed
after therapy with topoisomerase II inhibitors and characteristically presents as overt t-AML with recurrent balanced chromosome aberrations. Recent research suggests that these 2 general types of t-AML can now be
subdivided into at least 8 genetic pathways with a different etiology
and different biologic characteristics.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A. Knight, A. D. Skol, A. Shinde, D. Hastings, R. A. Walgren, J. Shao, T. R. Tennant, M. Banerjee, J. M. Allan, M. M. Le Beau, et al.
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility
Blood,
May 28, 2009;
113(22):
5575 - 5582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma
The changing classification of myelodysplastic syndromes: what's in a name?
Hematology,
January 1, 2009;
2009(1):
645 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Porter and J. DeGregori
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection
Blood,
December 1, 2008;
112(12):
4466 - 4474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Haematologica,
October 1, 2007;
92(10):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Azarova, Y. L. Lyu, C.-P. Lin, Y.-C. Tsai, J. Y.-N. Lau, J. C. Wang, and L. F. Liu
From the Cover: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
PNAS,
June 26, 2007;
104(26):
11014 - 11019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma
The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia
Haematologica,
June 1, 2007;
92(6):
723 - 727.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Melchert and A. F. List
Management of RBC-Transfusion Dependence
Hematology,
January 1, 2007;
2007(1):
398 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shannon and L. R. Silverman
Myelodysplastic syndrome and overlap syndromes
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
228 - 242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jawad, C. H. Seedhouse, N. Russell, and M. Plumb
Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia
Blood,
December 1, 2006;
108(12):
3916 - 3918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, et al.
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
N. Engl. J. Med.,
October 5, 2006;
355(14):
1456 - 1465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zebisch, P. B. Staber, A. Delavar, C. Bodner, K. Hiden, K. Fischereder, M. Janakiraman, W. Linkesch, H. W. Auner, W. Emberger, et al.
Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia.
Cancer Res.,
April 1, 2006;
66(7):
3401 - 3408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. I. Gordon
Flu redux and RIT: friendly fire in the treatment of low-grade lymphoma
Blood,
June 15, 2005;
105(12):
4543 - 4544.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Mistry, C. A. Felix, R. J. Whitmarsh, A. Mason, A. Reiter, B. Cassinat, A. Parry, C. Walz, J. L. Wiemels, M. R. Segal, et al.
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
N. Engl. J. Med.,
April 14, 2005;
352(15):
1529 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard
Insights into Leukemogenesis from Therapy-Related Leukemia
N. Engl. J. Med.,
April 14, 2005;
352(15):
1591 - 1594.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, D. H. Christiansen, and M. K. Andersen
Genetic Pathways in t-MDS and t-AML, a Revised Model.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
2993 - 2993.
[Abstract]
|
|
|
|
|
|
|
D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard
Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation
Blood,
September 1, 2004;
104(5):
1474 - 1481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Seedhouse, R. Faulkner, N. Ashraf, E. Das-Gupta, and N. Russell
Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia
Clin. Cancer Res.,
April 15, 2004;
10(8):
2675 - 2680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Beaumont, M. Sanz, P.M. Carli, F. Maloisel, X. Thomas, L. Detourmignies, A. Guerci, N. Gratecos, C. Rayon, J. San Miguel, et al.
Therapy-Related Acute Promyelocytic Leukemia
J. Clin. Oncol.,
June 1, 2003;
21(11):
2123 - 2137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Pineault, C. Buske, M. Feuring-Buske, C. Abramovich, P. Rosten, D. E. Hogge, P. D. Aplan, and R. K. Humphries
Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1
Blood,
June 1, 2003;
101(11):
4529 - 4538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Bowen, M. E. Frew, S. Rollinson, P. L. Roddam, A. Dring, M. T. Smith, S. E. Langabeer, and G. J. Morgan
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication
Blood,
April 1, 2003;
101(7):
2770 - 2774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. El-Osta, M. Lubbert, P. W. Wijermans, T. Licht, and P. A. Jones
On the use of DNA methylation inhibitors and the reversal of transcriptional silencing
Blood,
February 15, 2003;
101(4):
1656 - 1657.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Seedhouse, R. Bainton, M. Lewis, A. Harding, N. Russell, and E. Das-Gupta
The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia
Blood,
November 15, 2002;
100(10):
3761 - 3766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Qian, A. A. Fernald, L. A. Godley, R. A. Larson, and M. M. Le Beau
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia
PNAS,
November 12, 2002;
99(23):
14925 - 14930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Vardiman, N. L. Harris, and R. D. Brunning
The World Health Organization (WHO) classification of the myeloid neoplasms
Blood,
September 18, 2002;
100(7):
2292 - 2302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski
Acute Lymphoblastic Leukemia
Hematology,
January 1, 2002;
2002(1):
162 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
